Sign in Subscribe

rectal

A collection of 44 issues

FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer

Skip to content The CRC Digest ● REGULATORY FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer The accelerated approval covers stage II or III rectal cancer and is based on the AZUR-1 trial. At median follow-up of 26.3 months, 110 of 154 patients (71%) had received dostarlimab alone,

FDA grants accelerated approval to dostarlimab for MSI-H/dMMR locally advanced rectal cancer

Skip to content The CRC Digest ● REGULATORY FDA grants accelerated approval to dostarlimab for MSI-H/dMMR locally advanced rectal cancer On October 19, 2026, the FDA granted accelerated approval to dostarlimab for adults with Stage II/III locally advanced rectal cancer that is MSI-H or dMMR. The approval was based

Surgically treated early-onset rectal neuroendocrine neoplasms increased from 234 to 778 cases annually

Skip to content The CRC Digest Surgically treated early-onset rectal neuroendocrine neoplasms increased from 234 to 778 cases annually A National Cancer Database analysis of 7,285 patients under 50 who underwent surgery for rectal neuroendocrine neoplasms found that annual cases increased from 234 in 2004 to 778 in 2023,

Short-course vs long-course radiation: quality of life outcomes compared in rectal cancer

Skip to content The CRC Digest ♥ LIVING WITH CRC Short-course vs long-course radiation: quality of life outcomes compared in rectal cancer Researchers assessed longitudinal quality of life and functional outcomes using the EORTC QLQ-CR29 in rectal cancer patients treated with short-course radiation (25 Gy/5 fractions) versus long-course chemoradiation (50-50.

CRC Research Update — September 23, 2026

Today's colorectal cancer research highlights

CRC Research Update — September 18, 2026

Today's colorectal cancer research highlights

Chemoradiotherapy plus immunotherapy may expand checkpoint blockade benefit in mismatch repair-proficient rectal cancer

Skip to content The CRC Digest ◇ RESEARCH Chemoradiotherapy plus immunotherapy may expand checkpoint blockade benefit in mismatch repair-proficient rectal cancer Adding immune checkpoint blockade to chemoradiotherapy has been associated with pathological complete response rates of 30% or more in pMMR rectal cancer trials, higher than expected with chemoradiotherapy alone, though

Fatigue remains common five years after rectal cancer treatment

Skip to content The CRC Digest ♥ LIVING WITH CRC Fatigue remains common five years after rectal cancer treatment The QoLiRECT study investigated fatigue prevalence at 5 years after rectal cancer surgery using the Piper Fatigue Scale, examining baseline characteristics and treatment-related factors as potential predictors of moderate-severe fatigue. (Acta Oncol)

CRC Research Update — September 12, 2026

Today's colorectal cancer research highlights

PD-L1 blockade shows activity in MSS rectal cancer when combined with radiation and chemotherapy

Skip to content The CRC Digest ▸ TREATMENT PD-L1 blockade shows activity in MSS rectal cancer when combined with radiation and chemotherapy The PRECAM-R trial demonstrated that short-course radiotherapy may create an immune-priming window in microsatellite-stable tumors, allowing PD-L1 blockade to achieve a 44.8% pathologic complete response rate. (The ASCO